Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration

Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment†

“…No significant correlation observed between DFX plasma AUC and drug dose confirms the high PK individual differences, as previously shown . On the contrary, Lu et al . observed that twice‐daily DFX administration increased C trough compared with once‐daily route, suggesting that drug levels are dose related.…”

Quality by design approach for green HPLC method development for simultaneous analysis of two thalassemia drugs in biological fluid with pharmacokinetic study

“…A comparison between the proposed and reported methods 19,31 was conducted regarding greenness profile and is presented in Table 8 . From the comparison findings, the eight adopted metrics synergistically emphasized the green superiority of the proposed method, which showed an outstanding environmentally friendly method with more green than the reported methods.…”

The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major

“…Pongtanakul and Viprakasit () have shown that twice‐daily dosing of DFX significantly improves clinical efficacy in patients with TM who had inadequate responses to the standard once‐daily dose, with a significant decrease in SF. Recently, pharmacokinetic studies of DFX comparing once‐daily and twice‐daily administration found that twice‐daily administration of DFX increased the mean trough levels of DFX [183·8 (157·5) μmol/l] compared with once‐daily administration [87·7 (56·8) μmol/l] (Lu et al , ). However, more extensive trials are necessary to confirm these results.…”